Washington, D.C. 20549


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Peters Cameron

(Last) (First) (Middle)


(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
3. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
VP of Finance
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 861 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) (1) 01/30/2028 Common Stock 60,000 11.82 D
Explanation of Responses:
1. This option was granted on January 31, 2018. The shares underlying this option vested as to 25% of the shares on January 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter.
/s/ Christopher B. Primiano, Attorney-in-Fact for Cameron Peters 01/24/2019
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

      Know all by these presents, that the undersigned hereby 
makes, constitutes and appoints each of Christopher B. Primiano 
and Lee G. Giguere, signing singly and each acting individually, 
as the undersigned's true and lawful attorney-in-fact with full 
power and authority as hereinafter described to:
      (1)	execute for and on behalf of the undersigned, in the 
undersigned's capacity as an officer and/or a director of 
Karyopharm Therapeutics Inc. (the "Company"), Forms 3, 4, and 5 
(including any amendments thereto) in accordance with 
Section 16(a) of the Securities Exchange Act of 1934 and the 
rules thereunder (the "Exchange Act");
      (2)	do and perform any and all acts for and on behalf of 
the undersigned which may be necessary or desirable to prepare, 
complete and execute any such Form 3, 4, or 5, prepare, complete 
and execute any amendment or amendments thereto, and timely 
deliver and file such form with the United States Securities and 
Exchange Commission (the "SEC") and any stock exchange or 
similar authority, including without limitation the filing of a 
Form ID or any other application materials to enable the 
undersigned to gain or maintain access to the Electronic Data
Gathering, Analysis and Retrieval system of the SEC;
      (3)	seek or obtain, as the undersigned's representative 
and on the undersigned's behalf, information regarding 
transactions in the Company's securities from any third party, 
including brokers, employee benefit plan administrators and 
trustees, and the undersigned hereby authorizes any such third 
party to release any such information to the herein appointed 
attorney-in-fact and approves and ratifies any such release of 
information; and
      (4)	take any other action of any type whatsoever in 
connection with the foregoing which, in the opinion of such 
attorney-in-fact, may be of benefit to, in the best interest of, 
or legally required by, the undersigned, it being understood 
that the documents executed by such attorney-in-fact on behalf 
of the undersigned pursuant to this Power of Attorney shall be 
in such form and shall contain such terms and conditions as such 
attorney-in-fact may approve in such attorney-in-fact's 
      The undersigned hereby grants to each such attorney-in-fact 
full power and authority to do and perform any and every act and 
thing whatsoever requisite, necessary, or proper to be done in 
the exercise of any of the rights and powers herein granted, as 
fully to all intents and purposes as the undersigned might or 
could do if personally present, with full power of substitution 
or revocation, hereby ratifying and confirming all that such 
attorney-in-fact, or such attorney-in-fact's substitute or 
substitutes, shall lawfully do or cause to be done by virtue of 
this power of attorney and the rights and powers herein granted.  
The undersigned acknowledges that the foregoing 
attorneys-in-fact, in serving in such capacity at the request of 
the undersigned, are not assuming nor relieving, nor is the 
Company assuming nor relieving, any of the undersigned's 
responsibilities to comply with Section 16 of the Exchange Act.  
The undersigned acknowledges that neither the Company nor the 
foregoing attorneys-in-fact assume (i) any liability for the 
undersigned's responsibility to comply with the requirement of 
the Exchange Act, (ii) any liability of the undersigned for any 
failure to comply with such requirements, or (iii) any 
obligation or liability of the undersigned for profit 
disgorgement under Section 16(b) of the Exchange Act.
      This Power of Attorney shall remain in full force and 
effect until the undersigned is no longer required to file 
Forms 3, 4, and 5 with the SEC with respect to the undersigned's 
holdings of and transactions in securities issued by the 
Company, unless earlier revoked by the undersigned in a signed 
writing delivered to the foregoing attorneys-in-fact.
      IN WITNESS WHEREOF, the undersigned has caused this Power 
of Attorney to be executed as of this 17th day of January, 2019.

/s/ Cameron Peters
Cameron Peters